Huons Global's 'Hutox' Receives Approval for Phase 3 Clinical Trial in China

[Asia Economy Reporter Cho Hyun-ui] Huons Global announced on the 4th that on the 30th of last month, the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) approved the clinical trial protocol (IND) for the botulinum toxin product 'Hutox' (domestic name Riztox).

Through this, Huons Global plans to confirm the efficacy of Hutox in improving moderate to severe glabellar lines.

A Huons Global official stated, "Since Hutox was successfully launched after completing all clinical trials domestically, we expect the clinical trials in China to proceed smoothly as well."

Huons Global plans to complete the Phase 3 clinical trials in China by next year and obtain product approval from the NMPA in 2022 to launch Hutox in the Chinese market as soon as possible.

Kim Wan-seop, CEO of Huons Global, said, "With the approval of this clinical trial protocol, our entry into the Chinese market has entered a full-fledged track. Since we have experience and data from completing all clinical procedures domestically, we will proceed with the Phase 3 clinical trials in China without any setbacks."

This content was produced with the assistance of AI translation services.